Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer (BC)
with a poor prognosis. Current treatment options are limited to surgery, adjuvant …

The observation and analysis of intra-tumour heterogeneity (ITH), particularly in genomic
studies, has advanced our understanding of the evolutionary forces that shape cancer …

Futibatinib, a highly selective, irreversible FGFR1–4 inhibitor, was evaluated in a large
multihistology phase I dose-expansion trial that enrolled 197 patients with advanced solid …

Triple-negative breast cancer (TNBC), a highly aggressive subtype of breast cancer,
negatively expresses estrogen receptor, progesterone receptor, and the human epidermal …

Gastric cancer (GC) is a leading contributor to global cancer incidence and mortality.
Pioneering genomic studies, focusing largely on primary GCs, revealed driver alterations in …

Advances in cancer biology and sequencing technology have enabled the selection of
targeted and more effective treatments for individual patients with various types of solid …

To a large extent, cancer conforms to evolutionary rules defined by the rates at which clones
mutate, adapt and grow. Next-generation sequencing has provided a snapshot of the …

Intratumor heterogeneity, which fosters tumor evolution, is a key challenge in cancer
medicine. Here, we review data and technologies that have revealed intra-tumor …

Oesophageal cancer is the sixth most common cause of cancer-related death worldwide
and is therefore a major global health challenge. The two major subtypes of oesophageal …

Triple-negative breast cancer is a heterogeneous disease and specific therapies have not
been available for a long time. Therefore, conventional chemotherapy is still considered the …